Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Porro · SciRah

Researcher profile · Semantic Scholar

M. Porro

Share profile

M. Porro — researcher profile on SciRah

h-index: 14
Works: 27
Citations: 722

Most-cited papers

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
D. Bissett, J. Cassidy, Js De Bono, F. Muirhead +9 more
2004British Journal of Cancer123 citations Open access
Semantic Scholar
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
N. E. Schoemaker, C. van Kesteren, H. Rosing, S. Jansen +10 more
2002British Journal of Cancer113 citations Open access
Semantic Scholar
A Phase 2 Study of Intravenous Panobinostat in Patients With Castration-Resistant Prostate Cancer
D. Rathkopf, J. Picus, A. Hussain, S. Ellard +7 more
2013Cancer Chemotherapy and Pharmacology87 citations Open access
Semantic Scholar
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma
N. Sarapa, M. Britto, W. Speed, M. Jannuzzo +7 more
2003Cancer Chemotherapy and Pharmacology50 citations
Semantic Scholar
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
M. Slingerland, D. Hess, S. Clive, Sunil Sharma +7 more
2014Cancer Chemotherapy and Pharmacology47 citations
Semantic Scholar
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
P. Hamberg, Margaret M. Woo, Lin-Chi Chen, J. Verweij +7 more
2011Cancer Chemotherapy and Pharmacology45 citations Open access
Semantic Scholar
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
Fm Wachters, H. Groen, J. Maring, Ja Gietema +4 more
2004British Journal of Cancer45 citations Open access
Semantic Scholar
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer
G. Shapiro, R. Frank, U. Dandamudi, T. Hengelage +5 more
2011Cancer Chemotherapy and Pharmacology35 citations Open access
Semantic Scholar
Antiepileptic drug distribution in cerebral cortex, ammon's horn, and amygdala in man.
Vittorio A. Sironi, G. Cabrini, M. Porro, Luigi Ravagnati +1 more
1980Journal of Neurosurgery35 citations
Semantic Scholar
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
Sunil Sharma, P. Witteveen, M. Lolkema, D. Hess +6 more
2014Cancer Chemotherapy and Pharmacology33 citations Open access
Semantic Scholar
Plasma levels and clinical effects of antiepileptic drugs in pregnant epileptic patients and their newborns.
L. Bossi, B. Assael, G. Avanzini, D. Battino +14 more
1980Obstetrical and Gynecological Survey29 citations
Semantic Scholar
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
A. Sparreboom, M. D. de Jonge, C. Punt, K. Nooter +3 more
1998Clinical Cancer Research19 citations
Semantic Scholar
A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer
R. Feld, Margaret M. Woo, N. Leighl, F. Shepherd +6 more
2013Cancer Chemotherapy and Pharmacology17 citations
Semantic Scholar
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
V. Herben, R. van Gijn, J. Schellens, M. Schot +6 more
1999Journal of Clinical Oncology14 citations
Semantic Scholar
Clinical Relevance of Pharmacokinetics
G. Tognoni, C. Bellantuono, M. Bonati, M. D'Incalci +5 more
1980Clinical Pharmacokinetics12 citations
Semantic Scholar
Phenytoin: an inhibitor and inducer of primidone metabolism in an epileptic patient.
M. Porro, H. J. Kupferberg, Roger J. Porter, W. Theodore +1 more
1982British Journal of Clinical Pharmacology7 citations Open access
Semantic Scholar
Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): Implications for randomized phase II study design.
W. Mietlowski, Weichao Bao, P. Wood, Denise E. Williams +7 more
20124 citations
Semantic Scholar
Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study
Sunil Sharma, E. Voest, N. Hagner, P. Witteveen +8 more
20113 citations
Semantic Scholar
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.
A. Sparreboom, M. D. de Jonge, C. Punt, W. Loos +4 more
1999Drug Metabolism And Disposition2 citations Open access
Semantic Scholar
572 Oral panobinostat in patients with advanced tumors and impaired renal function: Relationship between pharmacokinetics and key safety parameters
M. Porro, Sunil Sharma, P. Witteveen, M. Lolkema +6 more
20141 citations
Semantic Scholar
A rank-based randomized phase II design when the phase III design is based on overall survival (OS).
W. Mietlowski, Fei Ma, Weichao Bao, Yunro Chung +3 more
20140 citations
Semantic Scholar
Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study
D. Hess, N. Hagner, S. Clive, H. Gelderblom +9 more
20110 citations
Semantic Scholar
Combinaisons comprenant un inhibiteur de cdk et un anticorps anti-facteur de croissance ou un antimitotique
Ciro Mercurio, Enrico Pesenti, M. Porro, Paolo Pevarello
20070 citations
Semantic Scholar
Methode d'administration d'un compose antitumoral
P. Gerletti, M. Porro, W. Speed
20010 citations
Semantic Scholar
[Causes and clinical aspects of neurological symptoms in the neonatal period].
R. Tornaghi, R. Sangermani, S. Baroni, A. Barbera +3 more
1982Minerva Pediatrica0 citations
Semantic Scholar
PHENYTOIN:AN INHIBITORAND INDUCER OFPRIMIDONE METABOLISM INAN EPILEPTICPATIENT
M. Porro, H. J. Kupferberg, R. Porter, W. Theodore +1 more
19820 citations
Semantic Scholar
[Histodynamics of neoplastic and pseudoneoplastic epidermis].
A. Tosti, P. Nazzaro, M. Porro
1968Minerva dermatologica0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Hess×5
Invite
D. Hess — researcher profile on SciRah
Sunil Sharma×5
Invite
Sunil Sharma — researcher profile on SciRah
Margaret M. Woo×5
Invite
Margaret M. Woo — researcher profile on SciRah
H. Gelderblom×4
Invite
H. Gelderblom — researcher profile on SciRah

×4

Invite

T. Hengelage — researcher profile on SciRah

Invite

W. Speed — researcher profile on SciRah

Invite

S. Mu — researcher profile on SciRah

Sue-zette Valera×3

Invite

Sue-zette Valera — researcher profile on SciRah

M. D. de Jonge×3

Invite

M. D. de Jonge — researcher profile on SciRah

Invite

L. Gazi — researcher profile on SciRah

P. Witteveen×3

Invite

P. Witteveen — researcher profile on SciRah

Invite

M. Lolkema — researcher profile on SciRah